By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Other immunostimulants > Beyfortus (cvx 307) > Nirsevimab Dosage
Other immunostimulants
https://themeditary.com/dosage-information/nirsevimab-dosage-12405.html

Nirsevimab Dosage

Drug Detail:Beyfortus (cvx 307) (Nirsevimab [ nir-sev-i-mab ])

Drug Class: Other immunostimulants

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Pediatric Dose for Respiratory Syncytial Virus

Recommended dosage:

  • Neonate and infants born during or entering their first respiratory syncytial virus (RSV) season: 50 mg intramuscularly once (for children less than 5 kg) or 100 mg intramuscularly once (for children 5 kg or greater)

  • Children up to 24 months of age who remain at increased risk for severe RSV in their second RSV season: A single 200 mg dose intramuscularly, administered as two 100 mg injections (2 x 100 mg).

  • Children undergoing cardiac surgery with cardiopulmonary bypass: An additional dose is recommended via intramuscular route as soon as the child is stable after surgery to ensure adequate vaccine serum levels.
  • In the first RSV season: If surgery is within 90 days after receiving the vaccine, the additional dose should be based on current body weight. See above for body weight dosing. If more than 90 days have elapsed since receiving the vaccine, the additional dose should be 50 mg regardless of body weight.
  • In the second RSV season: If surgery is within 90 days after receiving the vaccine, the additional dose should be 200 mg, regardless of body weight. If more than 90 days have elapsed since receiving the vaccine, the additional dose should be 100 mg regardless of body weight.

Use: For active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in neonates and infants born during or entering their first RSV season and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Precautions

CONTRAINDICATIONS: History of serious hypersensitivity reactions, including anaphylaxis to this vaccine or to any of its excipients.

Safety and efficacy have not been established in patients older than 24 months of age.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • For intramuscular administration only.
  • Do not use if the pre-filled syringe has been dropped or damaged, the security seal on the carton has been broken, or the expiration date has passed.
  • This vaccine can be administered in separate syringes and at different injection sites with other childhood vaccines. Do not mix with any vaccine or medication.
  • There is no information regarding co-administration with other immunoglobulin products.
  • Palivizumab should not be administered to infants who have received this vaccine in the same season.
  • Children who received palivizumab in their first respiratory syncytial virus (RSV) season and remain vulnerable to severe RSV disease can receive this vaccine prior to or during their second season.

Storage requirements:
  • Store in the refrigerator between 2C to 8C (36F to 46F). It must be used within 8 hours once removed from the refrigerator.
  • It may be kept at room temperature 20C to 25C (68F to 77F) for a maximum of 8 hours.
  • Store in the original carton and protect from light until time of use.
  • Do not freeze. Do not shake. Do not expose to heat.

Reconstitution/preparation techniques:
  • The manufacturer's product information should be consulted

Patient's caregiver advice:
  • Read Vaccine Information Statement (VIS) provided or available at (www.cdc.gov/vaccines).
  • Discuss and report possible adverse reactions with the healthcare provider.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by